alirocumab
AssetAlso called Praluent, Praluent (Alirocumab), Alirocumab (Solution), REGN727
Inhibits PCSK9, increasing LDL receptor recycling and lowering circulating LDL cholesterol.
- Stage
- Approved
- Modality
- Antibody
- Target
- PCSK9
- 18
- Indications
- 66
- Trials
- 2
- Developers
Approved by the FDA on Jul 24, 2015 (BLA125559). 2 approvals stand. FDA
Indications
18Hypercholesterolemia
Approved, EMA
Heterozygous familial hypercholesterolemia
Approved, FDA
Atherosclerotic cardiovascular disease
Approved, EMA
15 more
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials66
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.